210 related articles for article (PubMed ID: 17296974)
1. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.
Bosch F; Cantin G; Cortelezzi A; Knauf W; Tiab M; Turgut M; Zaritskey A; Merot JL; Tausch E; Trunzer K; Robson S; Gresko E; Böttcher S; Foà R; Stilgenbauer S; Leblond V
Leukemia; 2020 Feb; 34(2):441-450. PubMed ID: 31455851
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.
Palermo G; Maisel D; Barrett M; Smith H; Duchateau-Nguyen G; Nguyen T; Yeh RF; Dufour A; Robak T; Dornan D; Weisser M;
Blood Cancer J; 2015 Oct; 5(10):e353. PubMed ID: 26430724
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Gassner FJ; Weiss L; Geisberger R; Hofbauer JP; Egle A; Hartmann TN; Greil R; Tinhofer I
Cancer Immunol Immunother; 2011 Jan; 60(1):75-85. PubMed ID: 20857100
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Amrein PC; Attar EC; Takvorian T; Hochberg EP; Ballen KK; Leahy KM; Fisher DC; Lacasce AS; Jacobsen ED; Armand P; Hasserjian RP; Werner L; Neuberg D; Brown JR
Clin Cancer Res; 2011 May; 17(9):2977-86. PubMed ID: 21402714
[TBL] [Abstract][Full Text] [Related]
7. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.
Fürstenau M; Hallek M; Eichhorst B
Haematologica; 2019 Nov; 104(11):2144-2154. PubMed ID: 31585959
[TBL] [Abstract][Full Text] [Related]
8. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki AB; Koziner B; Chanan-Khan AA; Seymour JF; Gribben J; Itri LM; Rai KR
J Clin Oncol; 2009 Nov; 27(31):5208-12. PubMed ID: 19738118
[TBL] [Abstract][Full Text] [Related]
9. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC
J Clin Oncol; 2009 Dec; 27(35):6012-8. PubMed ID: 19826119
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC; Brown JR; O'Brien S; Barrientos JC; Kay NE; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Devereux S; Barr PM; Furman RR; Kipps TJ; Cymbalista F; Pocock C; Thornton P; Caligaris-Cappio F; Robak T; Delgado J; Schuster SJ; Montillo M; Schuh A; de Vos S; Gill D; Bloor A; Dearden C; Moreno C; Jones JJ; Chu AD; Fardis M; McGreivy J; Clow F; James DF; Hillmen P;
N Engl J Med; 2014 Jul; 371(3):213-23. PubMed ID: 24881631
[TBL] [Abstract][Full Text] [Related]
12. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman RR; Sharman JP; Coutre SE; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn I; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Stilgenbauer S; Cramer P; Aiello M; Johnson DM; Miller LL; Li D; Jahn TM; Dansey RD; Hallek M; O'Brien SM
N Engl J Med; 2014 Mar; 370(11):997-1007. PubMed ID: 24450857
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic cell signaling in cancer progression and therapy.
Plati J; Bucur O; Khosravi-Far R
Integr Biol (Camb); 2011 Apr; 3(4):279-96. PubMed ID: 21340093
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
16. Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2.
Gagliardi M; Ashizawa AT
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35056993
[TBL] [Abstract][Full Text] [Related]
17. Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes.
Yamada Y
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638486
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance.
Neophytou CM; Trougakos IP; Erin N; Papageorgis P
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503172
[TBL] [Abstract][Full Text] [Related]
19. Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions.
Salah HT; DiNardo CD; Konopleva M; Khoury JD
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34198580
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
